Although growth stock picks can be highly volatile, they can make good long-term investments. They may be well-known stars or quiet gems, but they do share one common attribute—they are growing at a higher-than-average rate within their industry, or within the market as a whole, and could keep growing for years or decades.
And keep in mind that we focus on growth stocks, which have a good long-term history and favourable prospects. We downplay momentum stocks that tend to attract many investors simply because they are moving faster than the market averages, but are liable to fall sharply when their momentum fades.
There’s room for growth stock investing in your portfolio, but make sure you follow our TSI Network three-part Successful Investor strategy for your overall portfolio:
- Invest mainly in well-established companies;
- Spread your money out across most if not all of the five main economic sectors (Manufacturing & Industry; Resources & Commodities; Consumer; Finance; Utilities);
- Downplay or avoid stocks in the broker/media limelight.
Make better stock picks when you read this FREE Special Report, Canadian Growth Stocks: WestJet Stock, RioCan Stock and More.
MP MATERIALS, $22.99, is still a buy. The company (New York symbol MP; TSINetwork Rating: Extra Risk) (www.mpmaterials.com; Shares o/s: 163.2 million; Market cap: $3.8 billion; No divids.) has commenced commercial production of neodymium-praseodymium (NdPr) metal and trial production of automotive-grade, sintered neodymium-iron-boron (NdFeB) magnets at its flagship Independence facility in Texas.
NdFeB magnets—the world’s most powerful and efficient permanent magnets—are essential components in vehicles, drones, robotics, electronics, and aerospace and defence systems.
Independence is now poised to produce 1,000 metric tons of finished NdFeB magnets per year, with a gradual production ramp-up beginning in late 2025....
ABBVIE INC., $197.35, is a buy. The company (New York symbol ABBV; TSINetwork Rating: Above Average) (www.abbvie.com; Shares outstanding: 1.8 billion; Market cap: $348.4 billion; Dividend yield: 3.3%) claimed the leading spot last year for TV drug ad spending; specifically, for commercials promoting its immunology blockbusters.
AbbVie’s Skyrizi claimed first place with nearly $377 million spent on 20 separate ads for the drug....
The pandemic presented both of these firms with unique challenges. However, each remained profitable and is well positioned to keep prospering as the economy continues to rebound. Trends now underway—as well as the strong position of these firms in key markets—will power their gains....
BROWN-FORMAN CORP., $31.00, (New York symbol BF.B; TSINetwork Rating: Average) (www.brown-forman.com; Shares o/s: 427.7 million; Market cap: $14.7 billion; Dividend yield: 2.9%) makes and sells alcoholic beverages....
Here are two companies that are already profitably taking advantage of AI, and they should be among the leaders in the push to extend AI’s use:
FAIR ISAAC CORP., $1,755.26, is a buy. The company (New York symbol FICO; TSINetwork Rating: Average) (www.fairisaac.com; Shares outstanding: 24.4 million; Market cap: $42.9 billion; No divd.) is best known for its FICO Scores software....
WELL HEALTH TECHNOLOGIES, $6.25, is a buy. The company (Toronto symbol WELL; TSINetwork Rating: Speculative) (www.well.company; Shares outstanding: 249.9 million; Market cap: $1.6 billion; No dividend paid) completed seven acquisitions in 2024....
STANTEC INC. $110 is a buy. This engineering firm (Toronto symbol STN; Aggressive Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 114.1 million; Market cap: $12.6 billion; Price-to-sales ratio: 1.8; Dividend yield: 0.8%; TSINetwork Rating: Extra Risk; www.stantec.com) has a new growth plan to mitigate the impact of climate change while making better use of digital technologies, including artificial intelligence, to improve efficiency.
The plan should lift the company’s annual revenue from about $5.8 billion in 2024 to $7.5 billion in 2026....